Chuck Royce's AXSM Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 94,017 shares of Axsome Therapeutics, Inc. (AXSM) worth $17.17 M, representing 0.17% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 27 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in AXSM, demonstrating sustained confidence in this investment. Largest addition occurred in Q1 2018, adding 75,000 shares. Largest reduction occurred in Q3 2018, reducing 556,000 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Axsome Therapeutics (AXSM) Holding Value Over Time
Track share changes against reported price movement
Quarterly Axsome Therapeutics (AXSM) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | +37,981 | Add 67.78% | 94,017 | $182.64 |
| Q3 2025 | +30,279 | Add 117.56% | 56,036 | $121.45 |
| Q2 2025 | -4,500 | Reduce 14.87% | 25,757 | $104.39 |
| Q1 2025 | -6,743 | Reduce 18.22% | 30,257 | $116.63 |
| Q4 2024 | +14,500 | Add 64.44% | 37,000 | $84.61 |
| Q3 2024 | +9,500 | Add 73.08% | 22,500 | $89.87 |
| Q1 2024 | +13,000 | New Buy | 13,000 | $79.80 |
| Q3 2021 | -20,300 | Sold Out | 0 | $0.00 |
| Q2 2021 | -5,400 | Reduce 21.01% | 20,300 | $67.44 |
| Q2 2020 | -14,400 | Reduce 35.91% | 25,700 | $82.30 |
| Q1 2020 | -20,000 | Reduce 33.28% | 40,100 | $58.83 |
| Q4 2019 | -44,600 | Reduce 42.60% | 60,100 | $103.36 |
| Q3 2019 | -10,000 | Reduce 8.72% | 104,700 | $20.24 |
| Q2 2019 | -67,700 | Reduce 37.12% | 114,700 | $25.75 |
| Q1 2019 | -150,000 | Reduce 45.13% | 182,400 | $14.23 |
| Q3 2018 | -556,000 | Reduce 62.58% | 332,400 | $3.45 |
| Q2 2018 | -67,600 | Reduce 7.07% | 888,400 | $3.20 |
| Q1 2018 | +75,000 | Add 8.51% | 956,000 | $2.45 |
| Q1 2017 | +881,000 | New Buy | 881,000 | $3.90 |
Chuck Royce's Axsome Therapeutics Investment FAQs
Chuck Royce first purchased Axsome Therapeutics, Inc. (AXSM) in Q1 2017, acquiring 881,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Axsome Therapeutics, Inc. (AXSM) for 27 quarters since Q1 2017.
Chuck Royce's largest addition to Axsome Therapeutics, Inc. (AXSM) was in Q1 2017, adding 881,000 shares worth $3.44 M.
According to the latest 13F filing for Q4 2025, Chuck Royce's firm, Royce & Associates Lp, owns 94,017 shares of Axsome Therapeutics, Inc. (AXSM), valued at approximately $17.17 M.
As of the Q4 2025 filing, Axsome Therapeutics, Inc. (AXSM) represents approximately 0.17% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Axsome Therapeutics, Inc. (AXSM) was 956,000 shares, as reported at the end of Q1 2018.